share_log

Imago BioSciences (NASDAQ:IMGO) Shares Gap Down to $15.29

Defense World ·  Oct 2, 2022 03:01

Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $15.29, but opened at $14.61. Imago BioSciences shares last traded at $15.26, with a volume of 105 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their price objective on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.

Get Imago BioSciences alerts:

Imago BioSciences Stock Performance

The company's 50-day moving average is $16.20 and its 200 day moving average is $16.33. The company has a market capitalization of $507.79 million, a PE ratio of -8.46 and a beta of 2.48.

Insider Activity at Imago BioSciences

In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $19.41, for a total transaction of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at approximately $2,888,382.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 8,168 shares of company stock valued at $155,402. 14.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Imago BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of IMGO. Ensign Peak Advisors Inc bought a new position in Imago BioSciences during the 4th quarter valued at about $593,000. Citadel Advisors LLC lifted its stake in Imago BioSciences by 20.1% during the 4th quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after acquiring an additional 410,487 shares during the period. Woodline Partners LP lifted its stake in Imago BioSciences by 101.9% during the 4th quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares during the period. Emerald Advisers LLC lifted its stake in Imago BioSciences by 7.0% during the 1st quarter. Emerald Advisers LLC now owns 616,368 shares of the company's stock valued at $11,877,000 after acquiring an additional 40,209 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in Imago BioSciences by 106.6% during the 1st quarter. New York State Common Retirement Fund now owns 13,391 shares of the company's stock valued at $258,000 after acquiring an additional 6,909 shares during the period. Institutional investors own 99.50% of the company's stock.

Imago BioSciences Company Profile

(Get Rating)

Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Let Paychex Stock Work Hard For You
  • Declining Profits Challenge the CarMax Value Proposition

Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment